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Purpose: In this study, we describe contrast sensitivity losses in the visual field of a patient 
affected by chloroquine toxicity, measured with stimuli favoring different visual mechanisms. 
We have compared these results with those of other, usual clinical tests.
Methods: The vision of a patient who underwent ten years of chloroquine treatment was ana-
lyzed by a battery of clinical tests: visual acuity (VA), Amsler’s grid, Farnsworth–Munsell 100-
hue test, spectral domain optical coherence tomography, multifocal electroretinogram (ERG), 
white-on-white and red-on-white Humphrey perimetries, chromatic and achromatic contrast 
sensitivity perimetry tests, and fluorescein angiography. Measurements were taken just before 
the cessation of the treatment, and 6 months later.
Results: The subjective visual perception of the patient was worse (in comparison with the rest 
of the visual field at the time of the first visit) in the center of the visual field, and was impaired 
on the second visit. Although standard automated perimetry (SAP) was practically normal and 
ERG results did not worsen with time, VA, Amsler’s grid, and visual fields with stimuli favoring 
the magnocellular and chromatic pathways signalled progressive loss of visual function.
Conclusions: Standard tests such as SAP or ERG may not detect visual field losses or 
progression of existing visual losses in a case of chloroquine toxicity, whereas tests evalu-
ating contrast sensitivity with stimuli favoring different visual mechanisms may be more 
sensitive.
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Introduction
The antimalarial drugs chloroquine and hydroxychloroquine have a well-established 
beneficial role in the treatment of rheumatoid arthritis, systemic lupus erythematosus,1,2 
and other connective tissue and skin disorders, but their use has been associated with 
the development of retinal toxicity.3 This ocular toxicity was first described in the 
literature as early as 1957, by Cambioggi et al.4
In the early stages of chloroquine retinal toxicity, there appear psychophysical 
signs of retinopathy, characterized by a paracentral scotoma on threshold visual field 
testing, without any observable fundus change; also, possibly, by the presence of color 
vision defects.5 Advanced retinopathy may show the typical “bull’s eye” maculopathy 
associated with impaired visual acuity and central visual field defects.6 These retinal 
changes are irreversible and may progress even after cessation of medication.7,8 
When the recommended dose of 3 mg chloroquine and 6.5 mg hydroxychloroquine 
per kilogram ideal body weight is not exceeded, the risk of retinopathy is low, but it 
increases with prolonged treatment.9
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The American Academy of Ophthalmology (AAO) 
recommends screening intervals after a baseline examina-
tion for both antimalarials, because of the anticipated risk 
to the patient.10 The proposed screening routine includes 
ophthalmological examination, far and near best-corrected 
visual acuities, and visual field testing (Humphrey 10-2 
perimetry). Optional tests include spectral domain optical 
coherence tomography (SDOCT), fundus autofluores-
cence (FAF), and multifocal electroretinogram (mfERG). 
However, there is only a limited number of studies that 
compare the sensitivity and specificity of these pro-
cedures relative to automated visual field testing. The 
optimal test or combination of tests is still unknown,11,12 
and the relative efficiency of quantitative tests like Hum-
phrey perimetry,10–12 mfERG or SDOCT is still under 
debate.13
Other alternative tests for detecting this form of 
retinopathy have been proposed. Xiaoyun et al14 recom-
mended analysis of the retinal nerve fiber layer thick-
ness with the GDx VCC scanning laser polarimeter, 
in order to detect early retinal damage. Recent studies 
show that chloroquine and hydroxychloroquine induce 
impairment in the sensitivity of the central retina that can 
be detected by microperimetry before retinal damage is 
visible.15,16
Although the guidelines of the AAO pay particular 
attention to structural damage and to the achromatic 
mechanism, defects in color vision are known to occur with 
antimalarial treatment that causes retinal toxic damage,5,17,18 
which may precede fundus alteration.18 However, reported 
changes may be subtle, and frequently are not detected by 
conventional color vision testing.19–24 The earliest color 
anomalies resulting from retinal toxicity occur along the 
blue-yellow (ie, tritan) direction of color space, while red-
green (protan) defects occur in more advanced cases.5,25,26 
For this reason, color vision tests exploring both opponent 
chromatic mechanisms, and capable of detecting slight 
discrimination changes, are needed to adequately charac-
terize these patients. Vu et al27 compared different clinical 
color vision tests on patients with established retinopathy 
and normal patients with rheumatic diseases and found 
that Standard Pseudoisochromatic Plates Part 2 had the 
best test characteristics for screening, yielding a sensitivity 
of 93% and a specificity of 88%. Neubauer et al5 showed 
that for advanced bull’s eye, color vision testing has 75% 
sensitivity and 91% specificity, even when oculograms are 
normal. They conclude that psychophysical tests are more 
effective for detecting alterations caused by chloroquine 
retinotoxicity.
However, most clinical color vision tests assess only 
central vision. It could be useful to compare the state of 
the different visual pathways of subjects under chloroquine 
treatment at different locations of the visual field. The first 
stages of visual perception are mediated by three parallel 
pathways of magnocellular, parvocellular, and koniocel-
lular origin, respectively, each encoding different visual 
information. Achromatic information is processed by both 
the magnocellular and parvocellular pathways, although the 
first mechanism is more sensitive to low spatial frequency 
and high temporal frequency stimuli, and mediates move-
ment perception. The second mechanism is most sensitive 
to stationary stimuli, and mediates shape perception and 
vision of spatial detail.28–32 Chromatic information is pro-
cessed by the red-green and blue-yellow opponent mecha-
nisms, respectively, of parvocellular and koniocellular 
origin.33 Though in clinical practice more attention is paid 
to losses in the achromatic mechanisms, acquired anoma-
lies in the chromatic mechanisms may seriously impair 
perception (for some demonstrative examples of the percep-
tion of subjects with damage in the chromatic mechanisms, 
see Capilla et al34).
In this study we present the case of an adult woman in 
a ten-year chloroquine treatment, just before cessation of 
the medication, and 6 months later. To take into account 
the effect of damage in different visual mechanisms, we 
have analyzed contrast sensitivity throughout the visual 
field, using stimuli with different chromatic and spatiotem-
poral characteristics. Measurements have been carried out 
using a computerized perimeter: the anthropometric test 
devices (ATD) Multichannel Functional Test, developed 
by the University of Valencia and INDO Internacional 
SA (Barcelona, Spain) (US Patent: 7.641.344 B2; Spanish 
Patent: 2246174).35,36
Case report
patient
The patient, a 59-year-old female, was diagnosed 10 years ago 
with ankylosing spondylitis and treated since then with chloro-
quine (150 mg/day). She was otherwise healthy, with no ante-
cedents of systemic or ophthalmological diseases. One year ago, 
she began to experience difficulty in reading. She also reported 
problems in far vision, especially in contrast discrimination. 
This patient was comparatively young when she began treat-
ment and has not taken other drugs during this period.
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Methodology
The procedures adhered to the tenets of the Declaration of 
Helsinki; the patient read and signed an informed consent 
form before any measurement.
The patient underwent the following test battery: 
tonometry, optical coherence tomography, angiography, 
measurement of best-corrected visual acuity (BCVA) with the 
Early Treatment Diabetic Retinopathy Study (ETDRS) test, 
color vision testing with the Farnsworth–Munsell 100-hue test 
under D-65 Illuminant, Amsler’s grid, mfERG, Humphrey 
24-2 visual field (with and without red filter), and ATD visual 
fields. All the measurements were taken on the first visit and 
6 months after the chloroquine treatment was interrupted.
Farnsworth–Munsell 100-hue test results are shown first 
as polar plots drawn with Farnsworth’s criterion and then 
smoothed with the procedure proposed by Dain and Birch,37,38 
to show the regions of relatively greater sensitivity losses. Total 
error scores (TES) were computed by summing the partial error 
scores for every cap. Total partial error scores were computed 
for the red-green (RG) axis using caps 13–33 and 55–75, 
and for the blue-yellow (BY) axis using caps 1–12, 34–54, 
and 76–85, as recommended by Smith et al.39 Normality limits 
for TES were those derived by Kinnear and Sahraie.40
The ATD Multichannel Functional Test has been 
described in detail in Anton and co-workers.35 Stimuli 
were generated on a colorimetrically-characterized and 
gamma-corrected 17-inch LG Flatron F700P CRT monitor, 
driven by a 12-bit video controller (Bits#; Cambridge 
Research Systems, Rochester, UK). Measurements were 
carried out in a darkened room. Patients were initially 
shown a spatially-uniform achromatic field, covering a 
60° horizontal by 40° vertical fovea-centered area, and 
were asked to fixate upon a central 0.5 degree wide black 
cross during the measurement session. After an adaptation 
period of 30 seconds, contrast sensitivity was assessed 
in 21 locations using flickering achromatic RG and BY 
gratings with Gaussian smoothed borders (see Figure 1 
for a description of the spatial and temporal profiles of the 
stimuli, an image of the four stimuli used in the study, and 
the spatial distribution of testing points). The screen was 
placed at 25 cm from the patient, who wore a 4.00 D addi-
tion, to avoid accommodation. The subject was instructed 
to press a button if any variation from the background was 
detected at any point of the visual field. Thresholds were 
determined by an interleaved stepwise threshold algorithm. 
At each trial, the testing point was changed at random. In 
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Figure 1 Typical spatial and temporal profiles of the stimuli generated in the ATD perimeter.
Notes: Left: example of spatial (top) and temporal (bottom) profile of the kind of stimulus used in the ATD perimeter. Right (top): single frames of the achromatic, red-green, 
and blue-yellow stimuli used in the measurements. The low spatial frequency achromatic stimulus corresponds to A(M) and the high-frequency one to A(P). Right (bottom): 
distribution of testing points in the visual field. At location (15°, -5°), a sample stimulus is shown, to give an indication of relative size.
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the first trial, at a given testing point, the stimulus had the 
maximum amplitude achievable by the CRT. If this stimulus 
was detected, amplitude was divided by 2 at that point in 
the next trial, and continued decreasing in this way until 
the subject failed to detect the stimulus. The staircase was 
then reversed and amplitude increased by 21/2 for the next 
presentation, and continued increasing in this way until the 
test was again detected. This triggered a second reversal, 
and amplitude was divided by 21/4, and so on. The criteria 
for exiting the staircase procedure at a given point were 
either totaling four reversals or 20 presentations, which-
ever came first. Among the stimuli presentations, up to 16 
false positive trials and 10 false negative trials were also 
randomly interleaved. Additionally, each session included 
up to 8 fixation losses catch trials, presented in the blind 
spot location previously estimated for the subject.
To favor different visual mechanisms, particular chroma-
ticities and spatiotemporal frequencies were chosen (see Anton 
et al35 for a detailed discussion). To evaluate the achromatic 
mechanism A, we used a stimulus favoring the magnocellular 
pathway (A: 0.5 cycles per degree [cpd], 12 Hz) and other 
stimulus stimulating the parvocellular pathway (A: 4 cpd, 
2 Hz). The RG and BY chromatic mechanisms, putatively 
mediated by the parvocellular and koniocellular pathways, 
respectively, were evaluated by stimuli modulated along the 
RG and BY directions of the Derrington Krauskopf Lennie 
(DKL) color space,41,42 with a spatial frequency of 0.5 cpd and 
a temporal frequency of 2 Hz (RG: 0.5 cpd, 2 Hz; BY: 0.5 cpd, 
2 Hz). Results were compared with a normal database of the 
same age range as the patient, and a total deviation map and 
a pattern deviation map, following the usual definitions, were 
plotted, with P-values codified in grayscale.
Results
First visit
In the first visit intraocular pressure (IOP) was 13 mmHg in 
both eyes. Both the angiography and the optical coherence 
tomography (OCT) were normal, but in the Amsler’s grid, 
the patient referred a diffuse central zone. BCVA values in 
LogMAR scale were 0.1 and 0.14, for the right and the left 
eyes, respectively. The Farnsworth–Munsell 100-hue test 
results showed significant generalized losses in all the color 
space (see Table 1 and Figure 2), with TES outside normal 
limits (P,0.05). The smoothed plots computed using Dain 
and Birch’s criterion37,38 (Figure 3) showed that, in both 
eyes, the defect appeared to be nonselective, affecting both 
Table 1 Farnsworth–Munsell Score
First visit Second visit
OD
 tes 184 (P,0.05) 172 (P,0.05)
 RG 92 98
 BY 92 74
Os
 tes 200 (P,0.05) 180 (P,0.05)
 RG 112 68
 BY 88 112
Notes: TES: total error score; RG: score for the red-green mechanism; BY: score for 
the blue-yellow mechanism. The RG and BY scores were computed following Smith 
et al.39 The normality limits used were those derived by Kinnear and Sahraie.40
Abbreviations: OD, right eye; OS, left eye.
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Figure 2 Results for Farnsworth–Munsell 100-hue test on the first visit.
Abbreviations: OD, right eye; OS, left eye.
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the RG and the BY mechanisms, although, in the left eye, 
a slightly greater loss in the RG than in the BY mechanism 
was suggested.
The visual field with the Humphrey white-on-white (SAP) 
was normal (Figure 4). There is not a normative database for 
the red-filter Humphrey perimetry, but the results show a local 
sensitivity decrease at the center of the visual field (Figure 5). 
The mfERG was consistent with the result of the red-on-white 
perimetry, since it was also altered in the center (results of 
wave P1 analysis, see Table 1).
The results of the perimetry tests for the four visual 
mechanisms on the first visit are shown in Figures 6 and 7. 
In all cases, the patient presented absolute sensitivity losses, 
more marked in the center of the visual field. The pattern 
deviation map showed relative losses in the central field, 
for both achromatic mechanisms, and isolated losses in the 
periphery for both chromatic mechanisms. Globally, the 
achromatic parvocellular pathway appeared to be the less 
affected.
second visit
At the second visit, BCVA was 0.14 and 0.2. IOP was 
12 mmHg and 13 mmHg, for the right and left eye, 
 respectively. In the OCT, we detected foveolar atrophy, and, 
in the Amsler’s grid, the patient reported a larger blurred area 
in the central region than on the first visit. The Farnsworth–
Munsell 100-hue test (Figure 8) showed that TES remained 
outside normal values. With the right eye, the defect seemed 
to selectively affect the RG mechanism; in the left eye, the 
BY mechanism was the more affected (see the Dain–Birch 
diagram and the error scores for the RG and BY mechanisms 
in Figure 3 and Table 2). This lack of consistency between 
the changes exhibited by both eyes can be seen more easily 
if we compare the partial total scores for the RG and BY 
mechanisms and the Dain–Birch diagrams from the first and 
second visits (Figure 3 and Table 1).
The results with the Humphrey perimeter are shown in 
Figures 9 and 10. There were no changes in the SAP peri-
metry, but, in the red-on-white perimetry, the size of the central 
region with sensitivity losses increased. The mfERG result 
was similar to the one obtained in the first visit (Table 2).
The four ATD perimetry tests for each eye are shown in 
Figures 11 and 12. For all stimuli, the size of the damaged 
central region increased, compared with the first visit. With 
both chromatic stimuli, the damage reached even the periph-
ery of the visual field.
Conclusions
In this study we examined how chloroquine toxicity affects 
visual perception, by analyzing the contrast sensitivity losses 
in different visual mechanisms. We have shown that even 
after cessation of treatment, the patient’s sensitivity steadily 
worsened, in agreement with previous studies,7,8 although not 
all of the techniques used with our patient were capable of 
revealing this progression.
We have paid particular attention to the behavior of the 
chromatic mechanisms. The Farnsworth–Munsell 100-hue 
test detects global color sensitivity losses affecting both 
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Figure 4 Total deviation and pattern deviation maps for SAP Humphrey perimetry on the first visit.
Notes: Top: right eye; Bottom: left eye.
Abbreviations: SAP, standard automated perimetry; OD, right eye; OS, left eye.
the RG and BY mechanisms, but describes a different 
progression in each eye. In the right eye, the BY mechanism 
slightly improved and, therefore, the RG component of the 
defect became more marked, whereas, in the left eye, the 
defect changed to a selective loss in the BY mechanism. 
However, the ATD chromatic perimetries show that both the 
RG and BY mechanisms were affected, and that the extent 
of visual field where this happened increased with time. This 
behavior is consistent with the shape of the red-on-white 
visual fields (Humphrey perimetry), where a depression at 
the central field was found at both visits.
The perimetry tests for the achromatic mechanisms do not 
show such extended damage. SAP perimetry does not detect 
many significant defects in the visual field, and the patient’s 
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Figure 8 Results for Farnsworth–Munsell 100-hue test on the second visit.
Abbreviations: OD, right eye; OS, left eye.
sensitivity at the center of the visual field seemed to improve 
with time. In the analogue perimetry in the ATD (parvocel-
lular achromatic mechanism), the patient exhibited smaller 
losses than for the other three stimuli; but, we can observe 
impairment with time. Two different explanations could be 
offered for this difference. To begin with, the detectability of 
the ATD stimulus is smaller than for the Goldman III stimu-
lus used in SAP, and this could highlight subtle defects that 
go unnoticed by SAP. A further reason may rest on the fact 
that SAP perimetry is not selective for a particular ganglion 
cell type.
The debate about the usefulness of visual function-
specific psychophysical tests in detection and follow-up of 
pathologies is still open. Current opinion is that detectable 
structural and functional changes can occur concurrently 
in some patients, whereas either structural or functional 
change is first apparent in others.43 Comparison of different 
psychophysical tests shows that, for a given pathology, not 
all subjects show damage or appear as normal in the same 
test types (see, for instance, Sample et al44). Even setting 
aside the objections that can be raised by the procedures 
used to compare the performance of different techniques, 
the first difficulty lies in how to ensure that the test really 
is function-specific (for a review of the hypothesis under-
lying each test, see Anderson45). For example, frequency 
doubling technology perimetry could serve to analyze the 
magnocellular pathway, high-pass resolution perimetry to 
analyze the parvocellular pathway, and short wavelength 
automated perimetry for the koniocellular pathway. This 
identification of visual tasks with particular cellular path-
ways is perhaps too simplistic (we refer the interested reader 
to Kaplan46). But admitting that these different techniques 
do favor different mechanisms, even if they are unable to 
completely isolate them, we find that neither the tasks car-
ried out by the patient nor the metrics used to express the 
results are comparable, making the analysis of the relative 
losses incurred by each mechanism difficult. The tests we 
show in this paper have, at least, the advantage of asking 
the patient to perform the same kind of task and of using 
the same metric for all the results.35
The case reported in this paper is meant to illustrate the 
fact that different psychophysical techniques should be used 
in combination, to gain a clear picture of the visual damage 
suffered by a particular patient. Even if the pathology is not 
mechanism-selective, the different visual functions are not 
equally sensitive to structural damage.44 Although structural, 
objective tests are often preferred by ophthalmologists, it has 
been argued that psychophysical testing, in spite of differ-
ent drawbacks, such as variability, is able to detect loss of 
function, even when the progression of structural damage 
seems to have been arrested.47 The guidelines of the AAO 
give particular relevance to structural damage and to the 
functions mediated by the achromatic mechanism; they are 
concerned with early detection, but not with how to moni-
tor the evolution of visual damage. The role of chromatic 
vision, either as an early indicator of damage and damage 
progression or as a key element in the patient’s everyday 
visual tasks, is undervalued. Measuring the sensitivity of 
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different visual pathways could be a good way to help us to 
understand the visual deficits of these patients, and may help 
to monitor their evolution.
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Figure 9 Total deviation and pattern deviation maps for SAP Humphrey perimetry, on the second visit.
Abbreviations: SAP, standard automated perimetry; OD, right eye; OS, left eye.
Table 2 Analysis of the wave P1 of the mfERG for both eyes and 
both visits
First visit Second visit
OD OS OD OS
R1 24.3 35.8 44.1 20.2
R2 14.4 11.8 11.5 24.7
R3 11.0 15.6 10.7 11.4
R4 7.5 10.2 9.2 11.9
R5 7.6 6.3 4.7 10.4
R6 5.8 5.5 4.0 7.7
Note: We present the density (nV/deg2) of each concentric ring (R1–R6).
Abbreviations: OD, right eye; OS, left eye; mfERG, multifocal electroretinogram.
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Figure 10 Grayscale sensitivity map for red-on-white Humphrey perimetry, on the second visit.
Abbreviations: OD, right eye; OS, left eye.
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Figure 11 ATD results for the right eye.
Notes: A(M): magnocellular mechanism; A(P): achromatic parvocellular mechanism; T(RG): opponent chromatic parvocellular mechanism; D(BY): koniocellular mechanism. 
top: total deviation map. Bottom: pattern deviation map.
Abbreviations: OD, right eye; A, achromatic; T (or RG), red-green opponent chromatic parvocellular mechanism; D (or BY), blue-yellow koniocellular mechanism green.
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Figure 12 ATD results for the left eye.
Notes: A(M): magnocellular mechanism; A(P): achromatic parvocellular mechanism; T(RG): opponent chromatic parvocellular mechanism; D(BY): koniocellular mechanism. 
top: total deviation map. Bottom: pattern deviation map. 
Abbreviations: OS, left eye; A, achromatic; T (or RG), red-green opponent chromatic parvocellular mechanism; D (or BY), blue-yellow koniocellular mechanism green.
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